vs
Apellis Pharmaceuticals, Inc.（APLS）与COLLEGIUM PHARMACEUTICAL, INC（COLL）财务数据对比。点击上方公司名可切换其他公司
COLLEGIUM PHARMACEUTICAL, INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$205.4M vs $199.9M），COLLEGIUM PHARMACEUTICAL, INC净利率更高（8.3% vs -29.5%，领先37.7%），COLLEGIUM PHARMACEUTICAL, INC同比增速更快（12.9% vs -5.9%），COLLEGIUM PHARMACEUTICAL, INC自由现金流更多（$122.4M vs $-14.3M），过去两年COLLEGIUM PHARMACEUTICAL, INC的营收复合增速更高（19.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Collegium制药是一家专科制药企业，专注于研发和商业化具备滥用威慑特性的创新疼痛管理疗法，主要面向美国市场，推出适用于慢性疼痛患者的缓释镇痛产品，服务覆盖基层及专科医疗领域的医护人员。
APLS vs COLL — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $205.4M |
| 净利润 | $-59.0M | $17.0M |
| 毛利率 | — | 62.5% |
| 营业利润率 | -25.6% | 29.6% |
| 净利率 | -29.5% | 8.3% |
| 营收同比 | -5.9% | 12.9% |
| 净利润同比 | -62.2% | 35.3% |
| 每股收益（稀释后） | $-0.40 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $205.4M | ||
| Q3 25 | $458.6M | $209.4M | ||
| Q2 25 | $178.5M | $188.0M | ||
| Q1 25 | $166.8M | $177.8M | ||
| Q4 24 | $212.5M | $181.9M | ||
| Q3 24 | $196.8M | $159.3M | ||
| Q2 24 | $199.7M | $145.3M | ||
| Q1 24 | $172.3M | $144.9M |
| Q4 25 | $-59.0M | $17.0M | ||
| Q3 25 | $215.7M | $31.5M | ||
| Q2 25 | $-42.2M | $12.0M | ||
| Q1 25 | $-92.2M | $2.4M | ||
| Q4 24 | $-36.4M | $12.5M | ||
| Q3 24 | $-57.4M | $9.3M | ||
| Q2 24 | $-37.7M | $19.6M | ||
| Q1 24 | $-66.4M | $27.7M |
| Q4 25 | — | 62.5% | ||
| Q3 25 | — | 61.7% | ||
| Q2 25 | — | 57.7% | ||
| Q1 25 | — | 54.8% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 62.5% | ||
| Q1 24 | — | 63.1% |
| Q4 25 | -25.6% | 29.6% | ||
| Q3 25 | 48.7% | 29.7% | ||
| Q2 25 | -18.6% | 18.7% | ||
| Q1 25 | -50.0% | 12.2% | ||
| Q4 24 | -12.3% | 20.9% | ||
| Q3 24 | -24.0% | 21.9% | ||
| Q2 24 | -14.7% | 32.7% | ||
| Q1 24 | -36.0% | 34.1% |
| Q4 25 | -29.5% | 8.3% | ||
| Q3 25 | 47.0% | 15.0% | ||
| Q2 25 | -23.6% | 6.4% | ||
| Q1 25 | -55.3% | 1.4% | ||
| Q4 24 | -17.1% | 6.9% | ||
| Q3 24 | -29.2% | 5.9% | ||
| Q2 24 | -18.9% | 13.5% | ||
| Q1 24 | -38.5% | 19.1% |
| Q4 25 | $-0.40 | $0.48 | ||
| Q3 25 | $1.67 | $0.84 | ||
| Q2 25 | $-0.33 | $0.34 | ||
| Q1 25 | $-0.74 | $0.07 | ||
| Q4 24 | $-0.30 | $0.36 | ||
| Q3 24 | $-0.46 | $0.27 | ||
| Q2 24 | $-0.30 | $0.52 | ||
| Q1 24 | $-0.54 | $0.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $386.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $301.7M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $386.7M | ||
| Q3 25 | $479.2M | $285.9M | ||
| Q2 25 | $370.0M | $222.2M | ||
| Q1 25 | $358.4M | $197.8M | ||
| Q4 24 | $411.3M | $162.8M | ||
| Q3 24 | $396.9M | $120.0M | ||
| Q2 24 | $360.1M | $271.6M | ||
| Q1 24 | $325.9M | $318.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $301.7M | ||
| Q3 25 | $401.2M | $274.8M | ||
| Q2 25 | $156.3M | $232.2M | ||
| Q1 25 | $164.2M | $234.4M | ||
| Q4 24 | $228.5M | $228.8M | ||
| Q3 24 | $237.1M | $234.3M | ||
| Q2 24 | $264.3M | $216.6M | ||
| Q1 24 | $266.7M | $222.2M |
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $123.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $122.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 59.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 7.25× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $327.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $123.0M | ||
| Q3 25 | $108.5M | $78.4M | ||
| Q2 25 | $4.4M | $72.4M | ||
| Q1 25 | $-53.4M | $55.4M | ||
| Q4 24 | $19.4M | $84.6M | ||
| Q3 24 | $34.1M | $-9.0M | ||
| Q2 24 | $-8.3M | $67.4M | ||
| Q1 24 | $-133.0M | $61.9M |
| Q4 25 | $-14.3M | $122.4M | ||
| Q3 25 | $108.3M | $78.3M | ||
| Q2 25 | $4.4M | $72.4M | ||
| Q1 25 | $-53.4M | $54.6M | ||
| Q4 24 | $19.3M | $84.1M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | $-8.4M | $67.1M | ||
| Q1 24 | $-133.3M | $61.4M |
| Q4 25 | -7.1% | 59.6% | ||
| Q3 25 | 23.6% | 37.4% | ||
| Q2 25 | 2.5% | 38.5% | ||
| Q1 25 | -32.0% | 30.7% | ||
| Q4 24 | 9.1% | 46.2% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | -4.2% | 46.2% | ||
| Q1 24 | -77.3% | 42.3% |
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.4% |
| Q4 25 | — | 7.25× | ||
| Q3 25 | 0.50× | 2.49× | ||
| Q2 25 | — | 6.05× | ||
| Q1 25 | — | 22.92× | ||
| Q4 24 | — | 6.75× | ||
| Q3 24 | — | -0.96× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 2.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
COLL
暂无分部数据
